
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type from the provided ranked marker list, I will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **CRISP3**: Known to be involved in immune response and inflammation.<br>- **CXCL13**: A chemokine involved in B-cell homing and lymphoid tissue organization.<br>- **EEF1A2**: A translation elongation factor, often associated with protein synthesis.<br>- **S100P**: A member of the S100 family, involved in calcium binding and signaling.<br>- **GJA1 (Connexin 43)**: Involved in gap junction communication.<br>- **FASN**: Fatty acid synthase, involved in lipid biosynthesis.<br>- **NQO1**: Involved in detoxification and antioxidant defense.<br>- **TRPS1**: A transcription factor involved in development and differentiation.<br>- **KRT19**: A type I keratin, often associated with epithelial cells.<br>- **HSPA1A**: A heat shock protein involved in stress response.<br><br>### Step 2: List the Key Cell Type Markers<br>- **CRISP3**: Often associated with prostate and salivary gland tissues, but also found in some breast cancer cells.<br>- **CXCL13**: Typically expressed in immune cells, particularly B-cells and follicular helper T-cells.<br>- **S100P**: Frequently expressed in various epithelial cancers, including breast cancer.<br>- **GJA1**: Commonly found in epithelial cells, including those in the breast.<br>- **KRT19**: A well-known marker for epithelial cells, particularly in breast tissue.<br>- **FASN**: Overexpressed in many cancer types, including breast cancer, due to increased lipid metabolism.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and recent literature on breast cancer scRNA-seq datasets, we can cross-reference these markers:<br>- **CRISP3, S100P, KRT19**: Frequently reported in breast cancer epithelial cells.<br>- **CXCL13**: While primarily an immune marker, its presence in the context of breast cancer may indicate tumor-associated immune cells or stromal interaction.<br>- **FASN, NQO1**: Overexpression is common in cancer cells, including breast cancer epithelial cells.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of markers like **KRT19, S100P, and FASN**, the most probable general cell type is **epithelial cells**, specifically those associated with breast tissue.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Breast Cancer Epithelial Cells**: Given the presence of markers like **KRT19, S100P, and FASN**, these are the most likely subtype.<br>2. **Luminal Epithelial Cells**: The expression of **KRT19** and **S100P** suggests a luminal origin, common in breast cancer.<br>3. **Basal-like Epithelial Cells**: While less likely due to the absence of specific basal markers, the presence of general epithelial markers could suggest this subtype.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of **breast cancer epithelial cells**, with a strong indication towards **luminal epithelial cells** due to the expression of markers such as **KRT19, S100P, and FASN**. These markers are commonly associated with breast cancer and epithelial cell identity, supporting the annotation of this cluster as luminal epithelial cells within the breast cancer context.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    To validate the annotation result, let's follow the outlined steps:<br><br>### Step 1: Marker Consistency<br>- **CRISP3, CXCL13, S100P, GJA1, FASN, NQO1, TRPS1, KRT19, HSPA1A**: All these markers are present in the provided marker list.<br>- The annotation identifies these markers as being associated with epithelial cells, particularly breast cancer epithelial cells, which is consistent with known literature.<br><br>### Step 2: Mixed Cell Type Consideration<br>- The annotation suggests a primary identification of breast cancer epithelial cells, with a focus on luminal epithelial cells.<br>- **CXCL13** is noted as an immune marker, which could indicate the presence of tumor-associated immune cells. However, the annotation considers this in the context of stromal interaction, which is reasonable given the context of breast cancer.<br>- No other strong evidence of mixed cell types is present based on the high-ranking markers provided.<br><br>### Conclusion<br>The annotation is consistent with the marker list and the known associations of these markers with breast cancer epithelial cells. The potential presence of immune-related markers like **CXCL13** is acknowledged and reasonably explained within the context of breast cancer.<br><br>Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">epithelial cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>breast cancer epithelial cells</li><li>luminal epithelial cells</li><li>basal-like epithelial cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a thorough and methodical approach to identifying the cell types present in the single-cell dataset derived from human breast cancer. The analysis effectively utilizes a range of markers to determine the most probable cell types, focusing on epithelial cells, particularly breast cancer epithelial cells, with a strong indication towards luminal epithelial cells. This is supported by the presence of key markers such as KRT19, S100P, and FASN, which are well-documented in the literature as being associated with breast cancer epithelial cells.<br><br>The annotation process shows a balanced consideration of multiple markers, rather than over-focusing on a specific one. For instance, while CRISP3 and CXCL13 are noted, the analysis appropriately contextualizes their presence within the broader framework of breast cancer, acknowledging potential stromal interactions and tumor-associated immune cells. This demonstrates an understanding of the complexity of tumor microenvironments and the potential for mixed cell populations.<br><br>The validation process further supports the accuracy of the annotation, confirming the consistency of the identified markers with known associations in breast cancer. The consideration of potential mixed cell types, such as the presence of immune-related markers, is acknowledged and reasonably explained, adding depth to the analysis.<br><br>However, there are a few areas where the analysis could be improved. The rank of the markers, which indicates their relative importance, could have been more explicitly considered in the final annotation. Additionally, while the annotation identifies potential subtypes like basal-like epithelial cells, it could have provided more detail on why these were considered less likely, given the absence of specific basal markers.<br><br>Overall, the annotation provides a comprehensive view of the cell types present, with a strong focus on the most relevant markers for breast cancer epithelial cells. The analysis is scientifically accurate and well-balanced, capturing the general picture of the cell populations effectively.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    